134 related articles for article (PubMed ID: 20480932)
1. Report from the 17th Conference on Retroviruses and Opportunistic Infections. Randomized studies of once-daily darunavir and tenofovir/FTC + nevirapine.
Sax PE
J Watch AIDS Clin Care; 2010 Apr; 22(4):33-4. PubMed ID: 20480932
[No Abstract] [Full Text] [Related]
2. Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.
Negredo E; Moltó J; Muñoz-Moreno JA; Pedrol E; Ribera E; Viciana P; Galindos MJ; Miralles C; Burger D; Rodriguez Fumaz C; Puig J; Gel S; Rodríguez E; Videla S; Ruiz L; Clotet B
Antivir Ther; 2004 Jun; 9(3):335-42. PubMed ID: 15259896
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-trial).
Weberschock T; Gholam P; Hueter E; Flux K; ; Hartmann M
Eur J Med Res; 2009; 14(12):516-9. PubMed ID: 20149984
[TBL] [Abstract][Full Text] [Related]
4. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of patients with initial early virologic failure after being treated with once-daily tenofovir/abacavir/lamivudine.
Khanlou H; Farthing C
AIDS Patient Care STDS; 2006 Sep; 20(9):604-5. PubMed ID: 16987045
[No Abstract] [Full Text] [Related]
6. [Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
Bayonne Kombo ES; Gathse A
Med Mal Infect; 2013 Mar; 43(3):134-5. PubMed ID: 23434355
[No Abstract] [Full Text] [Related]
7. Viral load decay in antiretroviral-naïve patients receiving once-daily tenofovir and emtricitabine plus twice-daily nevirapine.
Amoroso A; Gilliam BL; Talwani R; Boyce C; Redfield RR; Davis CE
HIV Clin Trials; 2009; 10(5):320-3. PubMed ID: 19906624
[TBL] [Abstract][Full Text] [Related]
8. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Suboptimal response to once-daily abacavir + 3TC + tenofovir.
Feinberg J
AIDS Clin Care; 2003 Nov; 15(11):94. PubMed ID: 14682272
[No Abstract] [Full Text] [Related]
9. Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.
Redfield RR; Morrow JS
Clin Infect Dis; 2008 Oct; 47(7):984-5. PubMed ID: 18778234
[No Abstract] [Full Text] [Related]
10. Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
Sabo JP; Kort J; Ballow C; Haschke M; Battegay M; Fuhr R; Girlich B; Schobelock M; Feifel U; Lang B; Li Y; Elgadi M
Clin Infect Dis; 2014 Nov; 59(10):1420-8. PubMed ID: 25091302
[TBL] [Abstract][Full Text] [Related]
11. Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.
Pulido F; Arribas JR; Hill A; Van Delft Y; Moecklinghoff C
Antivir Ther; 2011; 16(1):59-65. PubMed ID: 21311109
[TBL] [Abstract][Full Text] [Related]
12. Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients.
Droste JA; Kearney BP; Hekster YA; Burger DM
J Acquir Immune Defic Syndr; 2006 Jan; 41(1):37-43. PubMed ID: 16340471
[TBL] [Abstract][Full Text] [Related]
13. Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting.
Calcagno A; Bonora S; Tettoni MC; D'Avolio A; Perri GD; Lanzafame M; Penco G
J Acquir Immune Defic Syndr; 2009 Nov; 52(3):431-2. PubMed ID: 19858926
[No Abstract] [Full Text] [Related]
14. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
Lathouwers E; De Meyer S; Dierynck I; Van de Casteele T; Lavreys L; de Béthune MP; Picchio G
Antivir Ther; 2011; 16(1):99-108. PubMed ID: 21311113
[TBL] [Abstract][Full Text] [Related]
15. New once-daily HIV combination better tolerated.
Expert Rev Anti Infect Ther; 2004 Dec; 2(6):826. PubMed ID: 15566325
[No Abstract] [Full Text] [Related]
16. Tenofovir resistance among HIV-infected patients failing a fixed-dose combination of stavudine, lamivudine, and nevirapine in a resource-limited setting.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Chantratitra W
AIDS Patient Care STDS; 2007 Oct; 21(10):711-4. PubMed ID: 17949267
[No Abstract] [Full Text] [Related]
17. [3 years' data of tenofovir. Confirmed as a valuable building block].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():30-1. PubMed ID: 15373042
[No Abstract] [Full Text] [Related]
18. [HIV therapy and adherence].
Kuhlmann B
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():62-3. PubMed ID: 19024920
[No Abstract] [Full Text] [Related]
19. Investigating new antiretroviral combinations.
Carr A
J Infect Dis; 2006 Jun; 193(12):1742; author reply 1742-3. PubMed ID: 16703520
[No Abstract] [Full Text] [Related]
20. Tenofovir: a pill to prevent HIV?
Bonn D
Lancet Infect Dis; 2005 Feb; 5(2):78. PubMed ID: 15702509
[No Abstract] [Full Text] [Related]
[Next] [New Search]
